Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10341229 | 0.90 | THRB (0.49) | MAPK1MAPTMEN1KMT2AGAA | |
| SCHEMBL651326 | 0.89 | PDE5A (0.56) | MAPK1MAPTMEN1KMT2AGAA | |
| SCHEMBL1285507 | 0.86 | MAPT (0.51) | MAPK1MAPTMEN1KMT2AGAA | |
| SCHEMBL6200293 | 0.84 | MAPK1 (0.55) | MAPK1MAPTMEN1KMT2AGAA | |
| SCHEMBL1467161 | 0.84 | MAPK1 (0.65) | MAPK1MAPTMEN1KMT2AGAA | |
| SCHEMBL11066821 | 0.83 | MEN1 (0.51) | MAPK1MAPTMEN1KMT2AGAA | |
| SCHEMBL618410 | 0.82 | MAPT (0.62) | MAPTMEN1KMT2AGAARAB9A | |
| SCHEMBL1616605 | 0.82 | MAPK1 (0.53) | MAPK1MAPTMEN1KMT2AGAA | |
| SCHEMBL12850078 | 0.82 | MEN1 (0.50) | MAPK1MAPTMEN1KMT2AGAA | |
| SCHEMBL529424 | 0.82 | MAPK1 (0.66) | MAPK1MAPTMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115612309-A | Biheterocyclic diester-based azo disperse dye and preparation method thereof | 浙江博澳新材料股份有限公司 | 2023-01-17 | — | — | CN | claimed |
| CN-115612309-B | Double-heterocycle diester azo disperse dye and preparation method thereof | 浙江博澳新材料股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-115612309-A | Biheterocyclic diester-based azo disperse dye and preparation method thereof | 浙江博澳新材料股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-8440691-B2 | Tetrahydroquinolinyl compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBVIE INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2527339-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | Abbott Laboratories (US) | 2012-11-28 | — | — | EP | disclosed |
| US-20110152250-A1 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-7812019-B2 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBOTT LABORATORIES (US) | 2010-10-12 | — | — | US | disclosed |
| EP-1844038-A2 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006065484-A2 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128689-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128689-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | CACNA1E, CACNA1D, CACNA1S | MAPK1 817/4885MAPT 4880/4885MEN1 2383/4885 |
| US-20110152250-A1 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | CACNA1E, CACNA1D, CACNA1S | MAPK1 817/4885MAPT 4880/4885MEN1 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.